GW Announces UK Launch of World's First Prescription Cannabis Medicine

Porton Down, England, June 21, 2010 (ots/PRNewswire) - GW
Pharmaceuticals plc (GWP:AIM) today announces the UK launch of
Sativex(R), its Oromucosal Spray for the treatment of spasticity due
to Multiple Sclerosis (MS). Sativex(R) is the world's first
prescription cannabis medicine and the UK is the first country in the
world to grant a full regulatory authorization for the product.

Sativex(R) contains two cannabinoids or active ingredients - THC
(delta-9-tetrahydrocannabinol) and CBD (cannabidiol). It is the first
cannabinoid medicine derived from whole plant extracts from the
cannabis sativa plant.

Sativex(R), available as a prescription only medicine, was
developed by GW in specific response to calls from people with MS for
a prescription cannabis-based medicine. Today's launch means that MS
patients suffering the spasms and cramping associated with spasticity
have access to a new treatment option which has been shown to improve
their symptoms where current treatments have failed.

Sativex(R) is manufactured by GW under Home Office licence at an
undisclosed location in the UK. The medicine is being marketed in the
UK by GW's UK licensee, Bayer Schering Pharma.

Dr Geoffrey Guy, GW's Chairman, said: "The approval and launch of
Sativex(R) in the UK is the world's first full approval of a
cannabis-derived prescription medicine and the product of eleven
year's research by GW into the cannabinoid system. GW was founded
with the primary goal of developing a medicine to address the unmet
needs of people with MS and today's launch of Sativex(R) represents a
welcome advance in MS symptom treatment. This is also an historic
moment for GW and marks the beginning of the company's transition
from late stage development company to a commercial pharmaceutical
business. Today's news validates our cannabinoid technology platform
and enables us to progress the development of our pipeline across a
range of therapeutic areas with increased confidence."

Under the terms of the agreement with Bayer, GW will receive a
GBP10m milestone payment in respect of the UK approval of Sativex(R).

Outside the UK, Sativex is expected to be approved in Spain
shortly. Further submissions will be made in additional European
countries during the second half of 2010 under the mutual recognition
procedure. Almirall S.A. will market Sativex in Europe (ex-UK).

A series of photo images in connection with this story are
available to download at http://www.fovea.tv and/or call Peter Corbin
on +44(0)20-70892627.

Enquiries:

GW Pharmaceuticals plc (Today) +44-20-7831-3113
Dr Geoffrey Guy, Chairman +44-1980-557000
Justin Gover, Managing Director
GW PR
Financial Media: Ben Atwell / John Dineen +44-20-7831-3113
Other Media: Mark Rogerson +44-7885-638810
Bayer Schering Pharma +44-7711-200384
Cherry Wood / Kim Lemon (Liberation +44-7771-561079
Communications)
GW Advisers: Piper Jaffray Ltd +44-20-3142-8700
Neil Mackison / Rupert Winckler

For the full release including Note to Editors please visit:
http://www.gwpharm.com

ots Originaltext: GW Pharmaceuticals plc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Enquiries: GW Pharmaceuticals plc, Dr Geoffrey Guy,
Chairman,(Today) +44-20-7831-3113,, Justin Gover, Managing Director,
+44-1980-557000; GW PR, Financial Media: Ben Atwell / John Dineen,
+44-20-7831-3113 ;Other Media: Mark Rogerson, +44-7885-638810 ; Bayer
Schering Pharma,+44-7711-200384 ; Cherry Wood / Kim Lemon (Liberation
Communications),+44-7771-561079 ; GW Advisers: Piper Jaffray Ltd,
Neil Mackison / RupertWinckler, +44-20-3142-8700